Subscribe To
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome remain on track; Takeda anticipates regulatory […] The post Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates appeared first on ForexTV...
Read More
Posted: Nov 3 2023, 12:00
Author Name: forextv
Views: 112111